Performance Overview - Major indices showed strong performance in Q3, with Russell Microcap rising 17.0% and Russell 2000 increasing 12.4%, while DJIA rose only 5.6% [2] - Cedar Creek's performance was notable, with a 9.9% increase in Q3 and a year-to-date increase of 26.5%, outperforming all major indices tracked [2][5] Historical Returns - Cedar Creek's average annual return over 19.75 years is 14.80%, with cumulative returns since inception at 1,418.1% [3][5] - A $100,000 investment in Cedar Creek at inception would have grown to $1,518,112 by September 30, 2025, compared to $367,933 in Russell MicroCap and $977,972 in NASDAQ [6] Fund Holdings Valuation - As of September 2025, fund holdings were trading at 7.7 times estimated earnings for the coming year, with a trailing earnings multiple of 12.4 times [7] - The fund's weighted price-to-book ratio was 1.2, with a dividend yield of 1.5% and an expected return on equity of 15.4% [7] Cash Levels and Repositioning - Cash levels increased from 3% to 17% during the quarter, primarily due to the sale of PharmChem at $3.75 per share [8] - The fund sold shares in Citizens Bancshares to reallocate to perceived better opportunities, increasing its position in Phi Group [8] Investment Focus - The fund is focusing on smaller community banks, finding several trading at 5-6 times forward earnings estimates [9] - The fund's exposure to expert market stocks increased to 41%, with five positions making up about 87% of this exposure [11][13] Performance Attribution - The increase in valuation of expert market positions contributed significantly to the fund's performance, with a 26% increase in aggregate during the quarter [18] - Control positions increased in value by just over 4%, while generally undervalued securities rose by 7% [18] Updates on Specific Holdings - PharmChem was sold, yielding a total gross return of approximately 40% over two years [20] - Solitron Devices saw an increase in bid price from $15.75 to $16.40 per share, with bookings significantly exceeding sales in recent quarters [21][22] Other Fund Holdings - ENDI Corp's share price rose from $15.65 to $17.55 during Q3, with assets under management for CrossingBridge Advisors growing over 30% in 2024 [25][26] - The fair value estimate for ENDI continues to rise, with a valuation of $21.85 to $26.50 per share based on cash earnings [28]